Guth has Friedreich’s Ataxia and chose to raise money at Happy Place Nutrition for Friedreich’s Ataxia Research Alliance ...

When there are so few taxis in your regional city that you can actually use, it can be detrimental to your independence when ...

RBC Capital analyst Leonid Timashev upgraded Design Therapeutics (DSGN) to Outperform from Sector Perform with a price target of $13, up from $6.

The global Friedreich’s ataxia market is experiencing notable growth, fueled by advancements in genetic research, enhanced diagnostic technologies, and increased awareness of this rare ...

Comedian Fiona Cauley talks about turning 29 years old with a Friedreich's ataxia diagnosis, navigating the airport with a ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Larimar Therapeutics finds itself navigating a complex landscape of groundbreaking clinical progress against a backdrop of mounting financial pressures. The company's lead drug candidate, nomlabofusp, ...

Larimar Therapeutics ( ($LRMR) ) has provided an update. On November 10, 2025, Larimar Therapeutics announced an updated slide presentation ...

Leah Alstin’s rare neurodegenerative condition took her ability to walk independently, but that hasn’t stopped her from ...

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.

Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial ...

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.